Open AccessQuantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors
Author(s) -
Miguel F. Sanmamed,
Sara Fernández-Landázuri,
Carmen Rodríguez,
Ruth Zárate,
María D. Lozano,
Leyre Zubiri,
Jose Luis PérezGracia,
Salvador MartínAlgarra,
Álvaro González
Publication year - 2014
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2014.230235
Subject(s) - digital polymerase chain reaction , melanoma , mutation , basal (medicine) , medicine , progression free survival , gastroenterology , microbiology and biotechnology , cancer research , chemotherapy , biology , gene , polymerase chain reaction , genetics , insulin
Around 50% of cutaneous melanomas harbor the BRAF(V600E) mutation and can be treated with BRAF inhibitors. DNA carrying this mutation can be released into circulation as cell-free BRAF(V600E) (cfBRAF(V600E)). Droplet digital PCR (ddPCR) is an analytically sensitive technique for quantifying small concentrations of DNA. We studied the plasma concentrations of cfBRAF(V600E) by ddPCR in patients with melanoma during therapy with BRAF inhibitors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom